Quest Diagnostics Incorporated (DGX) Q2 2024 Earnings Call Transcript
Quest Diagnostics Incorporated (NYSE:DGX ) Q2 2024 Earnings Conference Call July 23, 2024 8:30 AM ET Company Participants Jim Davis - Chairman, Chief Executive Officer, President Sam Samad - Chief Financial Officer Shawn Bevec - Vice President of Investor Relations Conference Call Participants Ann Hynes - Mizuho Securities Kevin Caliendo - UBS Michael Cherny - Leerink Patrick Donnelly - Citi David Westenberg - Piper Sandler Erin Wright - Morgan Stanley Brian Tanquilut - Jeffries Lisa Gill - JP Morgan Michael Ryskin - Bank of America Jack Meehan - Nephron Research Andrew Brackmann - William Blair Pito Chickering - Deutsche Bank Stephanie Davis - Barclays Operator Welcome to the Quest Diagnostics Second Quarter 2024 conference call. At the request of the company, this call is being recorded.
Quest Diagnostics (DGX) Tops Q2 Earnings, Raises 2024 Outlook
Quest Diagnostics (DGX) delivers impressive base business growth in the second quarter of 2024.
Quest Diagnostics (DGX) Q2 Earnings and Revenues Top Estimates
Quest Diagnostics (DGX) came out with quarterly earnings of $2.35 per share, beating the Zacks Consensus Estimate of $2.31 per share. This compares to earnings of $2.30 per share a year ago.
Quest Diagnostics raises 2024 profit, revenue forecasts on health tests demand
Quest Diagnostics raised its 2024 profit and revenue forecasts on Tuesday, banking on robust demand for its health tests.
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out?
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Quest Diagnostics (DGX) Set to Acquire OhioHealth's Lab Services
Quest Diagnostics' (DGX) new agreement is likely to help expand access to cost-effective and advanced laboratory services in Ohio.
What Awaits Quest Diagnostics (DGX) in Q2 Earnings Release?
Quest Diagnostics (DGX) is likely to have maintained its robust base business performance in the second quarter of 2024. However, nosediving COVID-19 testing revenues may limit growth.
Quest Diagnostics (DGX) to Expand in Canada With LifeLabs Buyout
By integrating LifeLabs into its operations, Quest Diagnostics (DGX) aims to enhance the accessibility and quality of diagnostic services for Canadians.
Quest Diagnostics to acquire LifeLabs for $985 million
Quest Diagnostics said on Wednesday it would acquire LifeLabs, a provider of community laboratory tests, from OMERS for about C$1.35 billion, or about $985 million.
Quest Diagnostics to acquire Canada's LifeLabs for about $985 million including debt
Quest Diagnostics Inc. DGX, -0.33% said Wednesday it has entered a definitive agreement with pension fund OMERS to acquire LifeLabs, a Canadian provider of community laboratory services, for about C$1.35 billion ($985 million), including net debt. “Quest has supported laboratories, hospitals and academic centres in Canada with specialized testing services for over two decades, including during the COVID-19 pandemic,” said Jim Davis, Chairman and CEO of Secaucus, N.J.
Quest Diagnostics (DGX) Inks Deal to Acquire Allina Health
Quest Diagnostics (DGX) signs an agreement to acquire Allina Health's select laboratory assets. The deal is aimed at expanding Quest Diagnostics' laboratory services across Minnesota and western Wisconsin.
